Sermonix Surveys Find Vaginal/Sexual Health Symptoms Are Among Most Significant Issues Affecting Lives of ER+/HER2- Metastatic Breast Cancer Patients COLUMBUS, Ohio, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...

Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life Most patients minimized or hid side effects from their health care providers for fear of negative perceptions, reduced treatment efficacy, or being taken off a drug or out of a clinical trialSexual...